A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
Completed · Phase 1/Phase 2
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).
Key facts
- Study ID
- NCT06532032
- Run by
- Janssen Research & Development, LLC
- People needed
- 12
- Starts
- 2024-07-23
- Expected to finish
- 2026-05-14
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant must have histologically or cytologically confirmed NSCLC and must have metastatic NSCLC at the time of enrollment
- Participant must have at least 1 measurable lesion, according to RECIST v1.1, that has not been previously irradiated
- May have brain metastases only if previously definitively treated, and participant is clinically stable and asymptomatic for >2 weeks and is off or receiving low-dose corticosteroid treatment (<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment
- May have a prior malignancy (other than the disease under study) if the natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Have an ECOG performance status of 0 or 1
You may not qualify if…
- For Phase 2 only: Participant has known oncogenic driver mutations (EGFR, MET, HER2, ALK, ROS1, NTRK, BRAF, RET, or KRAS) as detected by local testing or by central ctDNA testing
- Participant has received radiotherapy for palliative purposes less than 14 days prior to the first dose of study treatment
- Participant has: a.(Or has a history of) leptomeningeal disease (carcinomatous meningitis); b. Spinal cord compression not definitively treated with surgery or radiation.
- Medical history of (non-infectious) ILD/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening- Participant has history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia) or has known allergies, hypersensitivity, or intolerance to: a. amivantamab or amivantamab excipients (refer to the amivantamab IB); b.docetaxel, docetaxel excipients or to other drugs formulated with polysorbate and paclitaxel
Where it is running
- UCI Health Irvine Hospital — Irvine, California, United States
- Cancer and Blood Specialty Clinic — Los Alamitos, California, United States
- University of California Irvine Medical Center Chao Family Comprehensive Cancer Center — Orange, California, United States
- Oncology Hematology Associates — Springfield, Missouri, United States
- Hunterdon Hematology Oncology — Flemington, New Jersey, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Changhua Christian Hospital — Changhua, Taiwan
- Kaohsiung Medical University Hospital — Kaohsiung City, Taiwan
- Chi Mei Medical Center Liu Ying — Liou Ying Township, Taiwan
- Taichung Veterans General Hospital — Taichung, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan
- Taipei Medical University — Taipei, Taiwan
- Ankara Bilkent Sehir Hastanesi — Çankaya, Turkey (Türkiye)
- Leeds Teaching Hospitals NHS Trust — Leeds, United Kingdom
- The Royal Marsden NHS Trust — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.